One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

CAR T-cell therapy shows promise for solid tumors like glioblastoma. New engineering strategies and clinical trial results ...

Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy. It uses a patient’s own immune system to fight certain blood cancers. Normal T cells can “hook” onto cancer cells and kill them, but ...

Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...

T cells engineered to express chimeric antigen receptors, known as CAR T cells, have been shown to help patients with blood cancer. A pivotal study 1 in 2011 used second-generation CAR T cells to ...

A growing body of research suggests that clinicians can offer chimeric antigen receptor (CAR) T-cell therapy safely and effectively on an outpatient basis — a positive development as clinicians ...

Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR ...

Celyad is a clinical-stage global leader in the development of chimeric antigen receptor (CAR)-T cell therapies for the treatment of cancer. The company is leading the next wave of CAR-T cell ...

CAR T-cell therapy, which uses genetically enhanced versions of a patient's own cancer-fighting T-cells, is revolutionizing ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ...